AurimMed Pharma, Inc. and Hövding Named First Recipients of Award and $25,000 Prizes
Landover, MD, July 11, 2013 – The Epilepsy Foundation, a national organization dedicated to serving all people with seizures, today launched the Epilepsy Innovation Seal of Excellence (SEAL), an award that recognizes groundbreaking and innovative product development programs deemed by the Foundation as deserving of significant and urgent support. The launch of the SEAL is part of the Foundation’s strategic mandate to recognize critical advancements in the field of epilepsy. The SEAL is designed to facilitate access to funding and resources that will carry the recipient’s work through proof of concept (PoC) and beyond, which typically costs from $1 million to $5 million dollars.
The award is given after intense scrutiny by the Scientific and Business Advisory Boards of the Epilepsy Foundation’s Epilepsy Therapy Project (ETP) Initiative. ETP is focused on identifying and accelerating the most innovative epilepsy products in development. The SEAL includes a prize of $25,000 and the privilege of using the Foundation’s Epilepsy Innovation Seal of Excellence in advancing their efforts (http://www.epilepsy.com/etp/seal_of_excellence).
The Epilepsy Foundation is honored to announce the recipients of the first two SEAL awards:
AurimMed Pharma of Park City, Utah is advancing an exciting anti-seizure drug AMP-X-0079 that has already demonstrated promising early-stage data in the National Institute of Neurological Disorders and Stroke (NINDS) Anticonvulsant Screening Program. The company is currently seeking $1.9 million to prepare AMP-X-0079 for an Investigational New Drug (IND) Application with the US Food and Drug Administration, taking this program into human clinical studies. (www.aurimmed.com)
The second SEAL recipient is Hövding of Malmö, Sweden for their revolutionary airbag helmet. The product was originally designed to protect cyclists, but also has the potential to offer significant safety features for people with epilepsy. The goal for Hövding is to obtain $4 million to adapt the bicycle device for falls during seizures and to make the airbag reusable. (www.Hovding.com)
“When it comes to money spent on research and innovation, the epilepsy community is tremendously underserved -- especially in comparison to medical conditions of similar or smaller prevalence,” said Roger J. Porter, MD, Chief Scientific Officer of the Epilepsy Foundation. “With this SEAL, we have recognized innovative projects in urgent need of funding and resources.”
The Epilepsy Innovation Seal of Excellence will be awarded biannually by the Epilepsy Foundation. Companies, investigators and researchers engaged in product development are encouraged to share research and product development programs of high merit and proof of concept with the Foundation (http://my.epilepsy.com/etp/seal_of_excellence/about).
“The Epilepsy Innovation Seal of Excellence represents our commitment to advancing important new products for the betterment of persons with epilepsy worldwide,” said Philip M. Gattone, President and CEO of the Epilepsy Foundation. “Our first prize winners were selected for their potential to improve the quality of life for people with epilepsy in a timeframe that matters. I hope support from the Epilepsy Foundation helps mobilize funding from other investors, government agencies and industry participants to make these important innovations real options for people with epilepsy. “
“The Epilepsy Therapy Project’s mandate is to accelerate pioneering epilepsy research, especially with near-term potential, and we recognize the need to assist in finding resources for critical but expensive innovations,” said Warren Lammert, Chairman of the Board of the Epilepsy Foundation. “The Epilepsy Innovation Seal of Excellence is an expression of our commitment to build the Epilepsy Foundation as a leader in driving new therapies and other innovations.”
When a person has two or more unprovoked seizures, they have epilepsy, which affects nearly three million people in the United States and 65 million people worldwide. This year, another 200,000 people in our country will be diagnosed with epilepsy. Despite all available treatments, four out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.
About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation’s goals are to ensure that people with seizures are able to participate in all life experiences; and to prevent, control and cure epilepsy through services, education, advocacy and research, so not another moment is lost to seizures.
To learn more about epilepsy, visit www.epilepsy.com. ‘Like’ the Epilepsy Foundation on Facebook at www.facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn
The Epilepsy Therapy Project is a 501 (c) (3) not-for-profit corporation dedicated to a singular focus: overcoming the funding gaps and roadblocks that slow the progress of new therapies from the lab to the patient. Epilepsy Therapy Project seeks to improve incentives and encourage commercial investment in new therapies. Acting as both a catalyst and clearing house for innovative research and the early commercialization of new therapies, the Epilepsy Therapy Project brings together financial resources, scientific insights and business expertise from leading academic and commercial industry participants.
Epilepsy Therapy Project has raised more than $6 million towards its mission.
The story of the Epilepsy Therapy Project, its founding in 2002 by parents of young children living with severe epilepsy, and the programs and therapies we have supported. Read moreOur Mission
Learn about the Epilepsy Therapy Project's mission, and why we need your help. Read moreWho We Are
To invest your contributions effectively, we have assembled an outstanding staff and team of clinicians, researchers, and pharmaceutical, biotechnology, and finance industry advisors. These scientific and business advisory board members make funding decisions and provide support to advance the most promising new therapy projects. Meet our teamepilepsy.com
Epilepsy.com is a dynamic online resource providing in-depth information and community for people living with epilepsy, and is the home of the Epilepsy Therapy Project. The mission of epilepsy.com is to inform and empower patients and families facing newly diagnosed epilepsy or those struggling with epilepsy that has resisted treatment. Read moreepilepsy.com professionals
An online resource for healthcare professionals to learn about epilepsy and seizures, co-existing disorders, specialized populations, and diagnosis and treatment for epilepsy. Visit our site for daily research and medical news about epilepsy, commentary from leading voices in the field, and opinions on controversial topics surrounding epilepsy research and treatment. Read more
A Message from Our Chairman and Co-Founder
Keeping a promise, and with thanks and appreciation, Warren Lammert, Chairman and Co-Founder offers some highlights of the Epilepsy Therapy Project's important accomplishments and progress. Read moreAnnual Report
Reflecting on the year behind us, this report features some of the programs that are supported through your contributions. Read more
The Epilepsy Therapy Project, a key program of the Epilepsy Foundation, supports innovative research in both academic and industry settings through direct grants and investments. Learn about our programs and how the Epilepsy Foundation is supporting research and helping to advance new therapies.
New Therapy - Commercialization Grants / Apply for Grant Funding
The mission of the New Therapy - Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups worldwide. The Program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program also encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source. Read more
Epilepsy Innovation Seal of Excellence
The Epilepsy Innovation Seal of Excellence awards are, like the New Therapy – Commercialization (NTC) program above, designed to accelerate the advancement of research from the laboratory to the patient. SEALs are provided to academic and commercial groups worldwide. The program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. Drug development may be stimulated at the early phases leading to an IND.
The Epilepsy Innovation Seal of Excellence award is not primarily a grant program. The program provides a competitive, in-depth review by the Scientific and Business Advisory Boards, an actual SEAL that may be used by the awardee to generate interest in the project, and a one-time $25,000 grant for the research. The SEAL is award for one year, renewable upon application, for up to a total of four years; the funding for this award is only provided for the first year. The applicants will typically have a research budget of between 1 and $5M for the overall project--amounts that currently exceed the resources of the Epilepsy Foundation. The Epilepsy Foundation will assist the awardees in finding funds for the selected projects. Read more
The Epilepsy Therapy Project directly supports promising new therapies and emerging epilepsy focused companies through research awards and equity investments. Review the list of funded projects and investments in this section. Read more
Other Sources of Funding
View the list of additional funding sources here. Read more
Learn more about the Epilepsy Therapy Project's upcoming events!
Epilepsy Therapy Project's past events
PharmaVoice highlights the story of ETP Founder and Chair, Warren Lammert and his daughter, Sylvie, who has uncontrolled seizures. Sylvie inspired Warren, Sylvie’s mother Kathy, and colleagues to initiate the Epilepsy Therapy Project, to accelerate development of new therapies for epilepsy. Read the story
|A Job Well Done - Ode to Robert Fisher and Hearty Welcome to Joe Sirven||10/04/2010|
|Epilepsy Pipeline Wiki: Time to make it happen||10/03/2010|
|Don't miss Epilepsy Talk Radio or the new Epilepsy Diary||4/25/2010|
|Sylvie turns 13. Shadow of 2 seizures on that special day||3/31/2010|
|A Year in Review - Happy Holidays from the Epilepsy Therapy Project||12/17/2009|
|Our new "My Epilepsy Diary" is live...||8/27/2009|
Start Your Own Epilepsy Group
Get connected and stay connected! Create a virtual meeting place for your organization or an existing epilepsy research group and deepen your connections using the Group Event Calender, Group Discussions and Shared Member Blogs.